on providing unique biodegradable implants with sustained drug delivery to improve patient outcomes and quality of life for patients suffering from ophthalmic diseases such as glaucoma.
The versatile Prezia Sustained Drug Delivery Technology platform is based on extensive scientific research that has resulted in the creation of a unique method for precise and controlled drug delivery.
PolyActiva has recently been awarded a $1.5m CUREator Grant, which will be used to progress its second generation ocular implant as a treatment for patients with glaucoma, targeting sustained daily dosing for 12 months.
PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.
The interim Phase 2a results demonstrate a sustained >20% reduction of IOP after 6 months with a favorable safety profile.
For more information on PolyActiva, please complete the form below:
© 2023 PolyActiva. All Rights Reserved. Caution: PolyActiva products are not for sale in the US